---

Comprehensive Notes on Lung Diseases

---

Classification Overview

1. Obstructive lung diseases - impaired airflow due to increased airway resistance (COPD, asthma, bronchiectasis, cystic fibrosis)
2. Restrictive lung diseases - reduced lung volume due to fibrosis or chest wall limitation (IPF, sarcoidosis, pneumoconioses)
3. Infectious diseases - pneumonia, tuberculosis, lung abscess
4. Vascular diseases - pulmonary embolism, pulmonary hypertension
5. Neoplastic diseases - lung cancer
6. Pleural diseases - pleural effusion, pneumothorax

---

1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Definition

Epidemiology

• Leading cause of morbidity and mortality worldwide
• Strong association with cigarette smoking (the primary risk factor)
• Also caused by occupational dust/fume exposure, biomass fuel smoke, and alpha-1 antitrypsin deficiency

Pathology

• Emphysema: loss of alveolar walls and their associated capillary beds; measurable by a reduction in DLCO and areas of low tissue density on CT scan
• Small airway disease: inflammation and fibrosis in airways <2 mm; most important site of airflow obstruction
• Chronic bronchitis: hypertrophied bronchial mucous glands, expanded goblet cell population, increased mucin - correlates with symptoms but NOT with airflow obstruction

Pathogenesis

1. Protease-antiprotease theory: primary mechanism for emphysema. Cigarette smoking recruits neutrophils and macrophages into the lung. These release elastolytic proteases (neutrophil elastase, macrophage elastases) that exceed antiprotease activity (especially alpha-1 antitrypsin). The result is elastin degradation and alveolar wall destruction.
   • Persons with alpha-1 antitrypsin deficiency (a serpin superfamily protein, the main inhibitor of neutrophil elastase) are at greatly elevated risk.
2. Oxidative stress: reactive oxygen species from cigarette smoke amplify the inflammatory signal
3. Vascular mechanisms: cigarette smoke causes intimal thickening and VEGF downregulation in septal vessels; VEGF manipulation in animal models can produce emphysema
4. Inflammatory persistence: the inflammatory response in the lung persists even after smoking cessation, supported by microbiome changes and evidence of autoimmunity

Pathophysiology

• Obstruction is located in small airways (<2 mm)
• Mechanisms: airway smooth muscle constriction, wall thickening and scarring, loss of parenchymal tethering (loss of elastic recoil), dynamic airway collapse
• Results in air trapping, hyperinflation, and the characteristic "coving" pattern on spirometry
• Hypoxemia leads to pulmonary vasoconstriction and eventually cor pulmonale (right heart failure)
• Gas exchange impairment: V/Q mismatch

GOLD Classification System

• Diagnosis requires a post-bronchodilator FEV1/FVC < 0.7
• Severity graded by FEV1 % predicted:
  • GOLD 1 (Mild): FEV1 ≥ 80%
  • GOLD 2 (Moderate): FEV1 50-79%
  • GOLD 3 (Severe): FEV1 30-49%
  • GOLD 4 (Very Severe): FEV1 < 30%
• Additionally stratified by symptoms (mMRC dyspnea scale, CAT score) and exacerbation history into Groups A, B, C, D

Clinical Features

• Progressive exertional dyspnea (cardinal symptom)
• Chronic productive cough
• Barrel chest, hyperinflation
• Prolonged expiration, pursed-lip breathing
• Decreased breath sounds, wheezing
• Signs of cor pulmonale in advanced disease: elevated JVP, peripheral edema, cyanosis

Treatment

• Smoking cessation (single most important intervention; slows decline in FEV1)
• Pulmonary rehabilitation
• Supplemental oxygen: for SaO2 < 88% or PaO2 < 56 mmHg continuously; reduces mortality, decreases polycythemia and pulmonary hypertension

• Triggers: viral URTIs (most common), bacterial infections, pollution
• Treatment: systemic corticosteroids (5-day course), short-acting bronchodilators, antibiotics when purulent sputum, non-invasive ventilation (NIV/BiPAP) for hypercapnic respiratory failure

---

2. ASTHMA

Definition

Pathogenesis

• Predominantly a Th2-mediated allergic inflammation: driven by IL-4, IL-5, IL-13
• Mast cell activation, eosinophil recruitment, IgE-mediated hypersensitivity
• Bronchoconstriction + mucus hypersecretion + mucosal edema
• Airway remodeling in chronic disease: goblet cell hyperplasia, subepithelial fibrosis, smooth muscle hypertrophy, increased mucus gland size

Triggers

• Allergens (house dust mite, animal dander, mold, cockroach)
• Respiratory infections (viral URTIs are the most common trigger of exacerbations)
• Exercise, cold air
• Aspirin/NSAIDs (aspirin-exacerbated respiratory disease)
• Occupational exposures
• Emotional stress

Classification (GINA-based)

• Intermittent: symptoms <2 days/week, no nighttime awakening, FEV1 ≥ 80%
• Persistent Mild: symptoms >2 days/week, FEV1 ≥ 80%
• Persistent Moderate: daily symptoms, nighttime awakening >1x/week, FEV1 60-79%
• Persistent Severe: continuous symptoms, frequent nighttime awakening, FEV1 < 60%

Clinical Features

• Episodic dyspnea, wheezing (bilateral polyphonic), chest tightness, cough (worse at night)
• Prolonged expiration
• Spirometry shows reversible obstruction: FEV1/FVC < 0.7 with ≥12% + ≥200 mL improvement post-bronchodilator

Spirometry Findings

• Obstructive pattern: reduced FEV1/FVC
• Reversibility with bronchodilator
• Bronchial provocation test (methacholine challenge) to confirm hyperresponsiveness when spirometry is normal

Treatment

• Step-up therapy based on severity
• SABAs (albuterol) for acute relief (all patients)
• Low-dose ICS: first controller therapy
• ICS + LABA: moderate-to-severe persistent
• Biologics for severe eosinophilic asthma: omalizumab (anti-IgE), mepolizumab/benralizumab (anti-IL-5/IL-5Rα), dupilumab (anti-IL-4Rα)
• Acute exacerbation: SABA nebulization, IV/oral corticosteroids, oxygen, heliox in severe cases

---

3. BRONCHIECTASIS

Definition

Etiology

• Cystic fibrosis (most common genetic cause in young patients)
• Post-infectious (childhood pertussis, measles, tuberculosis)
• Allergic bronchopulmonary aspergillosis (ABPA)
• Hypogammaglobulinemia, primary ciliary dyskinesia
• Rheumatoid arthritis, Sjogren syndrome
• Idiopathic (significant proportion)

Clinical Features

• Chronic productive cough with large volumes of mucopurulent sputum ("3 layers" on standing: frothy top, mucopurulent middle, dense purulent bottom)
• Hemoptysis (can be massive)
• Recurrent respiratory infections
• Crackles on auscultation

Diagnosis

• High-resolution CT (HRCT) of chest: gold standard - shows "signet-ring sign" (bronchial lumen wider than adjacent pulmonary artery), lack of bronchial tapering, visible bronchi in periphery of lung

Treatment

• Airway clearance (chest physiotherapy, oscillating PEP devices)
• Macrolide antibiotics for chronic suppression
• Inhaled antibiotics (tobramycin, aztreonam) in CF and Pseudomonas colonization
• Treat underlying etiology

---

4. CYSTIC FIBROSIS (CF)

Definition

Epidemiology

• Most common life-shortening genetic disease in White populations
• Incidence: ~1:2500-3000 live births in Northern Europe/Americas
• F508del mutation accounts for ~70% of all affected alleles; over 2000 mutations identified

CFTR Mutation Classes

Clinical Manifestations

• Chronic productive cough, crackles, wheezing
• Recurrent pulmonary exacerbations (triggered by viral infections)
• Progressive bronchiectasis (predominantly upper lobes)
• Colonization with Staphylococcus aureus (early), then Pseudomonas aeruginosa (chronic), Burkholderia cepacia (poor prognosis)
• Cor pulmonale in advanced disease
• Hemoptysis, pneumothorax as complications

• Meconium ileus (15-20% of neonates)
• Pancreatic insufficiency in 90% - fat malabsorption, fat-soluble vitamin deficiency (A, D, E, K)
• Distal intestinal obstruction syndrome (DIOS)
• Liver disease/cirrhosis in ~5%

Diagnosis

• Sweat chloride test: >60 mEq/L diagnostic
• Genetic testing for CFTR mutations
• Newborn screening (immunoreactive trypsinogen)

Treatment

• Ivacaftor (potentiator) - for Class III gating mutations (G551D); restores CFTR channel opening
• Lumacaftor/ivacaftor (corrector + potentiator) - for F508del homozygotes
• Elexacaftor/tezacaftor/ivacaftor (ETI, Trikafta) - triple combination; highly effective for F508del; approved for patients ≥6 years with at least one F508del allele; dramatically improves lung function and quality of life

• Mucolytics: inhaled dornase alfa (DNase; cleaves neutrophil-derived extracellular DNA to reduce sputum viscosity) and hypertonic saline
• Airway clearance: chest physiotherapy, oscillating vests
• Antibiotics (inhaled tobramycin, aztreonam; IV antipseudomonal agents for exacerbations)
• Bronchodilators: inhaled beta-agonists + anticholinergics
• Azithromycin 3x/week for immunomodulatory effect
• High-dose ibuprofen (patients <18 years with FEV1 <60%) to slow decline

---

5. IDIOPATHIC PULMONARY FIBROSIS (IPF)

Definition

Epidemiology

• Affects adults >50 years (virtually never before 50)
• More common in males
• Similar UIP pathology can be seen in asbestosis and collagen vascular diseases - these must be excluded

Pathogenesis

• Repeated alveolar epithelial injury + defective repair in a genetically predisposed individual
• Germline mutations in telomerase genes (cellular senescence promotes profibrotic phenotype)
• Genetic variant in MUC5B gene (altered mucin production) in ~35% of cases
• Mutations in surfactant genes (expressed only in lung epithelial cells - confirm epithelial origin)
• Abnormal epithelial repair leads to exuberant fibroblast/myofibroblast proliferation and collagen deposition
• Key mediators: TGF-β (excessive profibrotic activation), M2-polarized alveolar macrophages (secrete cytokines promoting fibroblast activation)

Morphology

• Gross: cobblestoned pleural surface; firm, rubbery white areas on cut section
• Microscopic (hallmarks):
  • Patchy interstitial fibrosis of varying density (temporal heterogeneity: early + late lesions coexist)
  • Fibroblastic foci (early lesions): active fibroblast proliferation
  • Honeycomb fibrosis (late): cystic spaces lined by hyperplastic type II pneumocytes or bronchiolar epithelium
  • Alveolar septal infiltrates with lymphocytes, plasma cells, mast cells
  • Secondary pulmonary hypertensive changes (intimal fibrosis of pulmonary arteries)
  • Subpleural and basilar distribution - characteristic pattern

Clinical Features

• Gradual onset of non-productive cough and progressive dyspnea
• Classic "Velcro-like" or "dry" bibasilar crackles on auscultation
• Digital clubbing (~50%)
• Advanced disease: cyanosis, cor pulmonale, peripheral edema

Diagnosis

• HRCT chest: subpleural and basilar fibrosis, reticular abnormalities, honeycombing ± traction bronchiectasis
• Surgical lung biopsy: if HRCT is atypical; shows UIP pattern
• PFTs: restrictive pattern (reduced TLC, FVC, DLCO); FEV1/FVC normal or elevated

Treatment

• Antifibrotic agents - slow rate of decline:
  • Nintedanib (pan-tyrosine kinase inhibitor targeting PDGFR, VEGFR, FGFR) - decreases FVC decline
  • Pirfenidone (anti-inflammatory, antifibrotic) - also reduces FVC decline
• Supplemental O₂ for hypoxemia
• Pulmonary rehabilitation
• Lung transplantation (definitive option for eligible patients)
• NO role for corticosteroids or immunosuppressants (shown to be harmful)
• Prognosis: median survival 3-5 years after diagnosis

---

6. PNEUMONIA

Definition

Common Pathogens

Clinical Features

• Typical pneumonia: acute onset fever, rigors, pleuritic chest pain, productive purulent cough (rusty sputum with S. pneumoniae), lobar consolidation on CXR
• Atypical pneumonia ("walking pneumonia"): insidious onset, dry cough, mild systemic symptoms, patchy infiltrates on CXR - often worse on CXR than clinical exam suggests

Investigations

• CXR: consolidation, infiltrates, or interstitial pattern
• Blood cultures, sputum Gram stain and culture
• Urinary antigen (pneumococcal, Legionella)
• CBC: neutrophilia in bacterial; lymphopenia in viral; eosinophilia may suggest fungal
• ABG in severe disease
• Procalcitonin: elevated in bacterial pneumonia

Severity Scoring

• PSI (Pneumonia Severity Index): risk classes I-V; guides hospitalization decision
• CURB-65: Confusion, Urea >7 mmol/L, Respiratory rate ≥30, Blood pressure <90/60, age ≥65. Score ≥2 = hospitalization; ≥3 = ICU consideration

Treatment

• CAP (outpatient): Amoxicillin ± macrolide or doxycycline (low severity); quinolone (moderate)
• CAP (inpatient): beta-lactam + macrolide, or respiratory quinolone
• CAP (severe/ICU): beta-lactam + macrolide or fluoroquinolone ± anti-MRSA coverage
• HAP/VAP: antipseudomonal beta-lactam + anti-MRSA coverage based on local resistance patterns
• Duration: 5-7 days for most CAP; longer for Legionella, severe cases

---

7. TUBERCULOSIS (TB)

Pathogen

Primary TB

• Initial infection after inhalation; focus in mid-lung zones (Ghon focus)
• Ghon focus + draining lymph nodes = Ghon complex (Ranke complex)
• Usually self-limited; heals by fibrosis and calcification
• Latent TB: viable organisms persist in granulomas for years

Post-Primary (Reactivation) TB

• Classically involves upper lobes (high O₂ tension)
• Manifestations: caseating granulomas, cavitation
• Symptoms: night sweats, low-grade fever, weight loss, productive cough, hemoptysis
• Spread: hematogenous (miliary TB), lymphatic, contiguous

Diagnosis

• Sputum smear (AFB stain) and culture (gold standard)
• GeneXpert MTB/RIF (rapid PCR; detects rifampicin resistance)
• Tuberculin skin test (TST/Mantoux) and IGRA (QuantiFERON-TB Gold) for latent TB
• CXR: upper lobe infiltrates, cavitation, hilar adenopathy, miliary pattern

Treatment

• Intensive phase (2 months): Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) + Ethambutol (E) = 2HRZE
• Continuation phase (4 months): Isoniazid + Rifampicin = 4HR
• Pyridoxine (B6) given with isoniazid to prevent peripheral neuropathy

---

8. PULMONARY EMBOLISM (PE)

Definition

Risk Factors (Virchow's Triad)

• Stasis: immobility, heart failure, long-distance travel
• Hypercoagulability: malignancy, OCP, pregnancy, Factor V Leiden, antiphospholipid syndrome
• Endothelial injury: surgery, trauma

Pathophysiology

• Clot obstructs pulmonary artery → V/Q mismatch → hypoxemia
• Increased dead space → hypocapnia, then hypercapnia in massive PE
• Right heart strain → elevated right heart pressures → if severe, obstructive shock

Clinical Features

• Massive PE: sudden onset severe dyspnea, pleuritic chest pain, syncope, hypotension, tachycardia
• Submassive PE: moderate dyspnea, tachycardia, right heart strain on Echo
• Small PE: pleuritic chest pain, hemoptysis (pulmonary infarction)
• Pleural rub, raised JVP, right heart gallop in severe cases

Investigations

• D-dimer: high sensitivity, low specificity; negative D-dimer excludes PE if clinical probability is low
• CT pulmonary angiography (CTPA): gold standard imaging
• ECG: sinus tachycardia (most common); S1Q3T3 pattern; right bundle branch block
• Troponin and BNP: elevated in massive PE (right ventricular strain markers)
• V/Q scan: alternative when CTPA contraindicated (renal failure, contrast allergy)

Treatment

• Anticoagulation (mainstay): heparin bridging to warfarin, or DOACs (rivaroxaban, apixaban)
• Thrombolysis (tPA): for massive PE with hemodynamic compromise
• Surgical embolectomy / catheter-directed thrombolysis: for failed thrombolysis or contraindications
• Duration of anticoagulation: 3 months for provoked PE; indefinitely for unprovoked or hypercoagulable states

---

9. PULMONARY HYPERTENSION (PH)

Definition

WHO Classification (5 Groups)

1. Group 1 - PAH: idiopathic, heritable (BMPR2 mutation), drug/toxin-induced, connective tissue disease
2. Group 2 - Left heart disease (most common cause)
3. Group 3 - Lung disease/hypoxia (COPD, IPF)
4. Group 4 - Chronic thromboembolic PH (CTEPH)
5. Group 5 - Unclear/multifactorial mechanisms (sarcoidosis, thyroid disorders)

Pathophysiology (PAH)

• Pulmonary vascular remodeling: smooth muscle hypertrophy, intimal proliferation, adventitial fibrosis
• Endothelial dysfunction: decreased prostacyclin and NO; increased endothelin-1
• Elevated PVR → progressive right heart failure

Clinical Features

• Progressive dyspnea, fatigue, syncope on exertion
• Loud P2, right-sided S3/S4, right heart failure signs

Treatment (Group 1 PAH - specific)

• Calcium channel blockers (only for vasoreactive patients on acute vasodilator testing)
• Endothelin receptor antagonists: bosentan, ambrisentan, macitentan
• PDE-5 inhibitors: sildenafil, tadalafil
• Soluble guanylate cyclase stimulator: riociguat
• Prostacyclin analogues: epoprostenol (IV), iloprost (inhaled), treprostinil
• Lung transplantation for refractory disease

---

10. LUNG CANCER

Types and Frequency

Risk Factors

• Cigarette smoking (dominant risk factor; accounts for ~85% of lung cancers)
• Radon gas exposure
• Occupational carcinogens: asbestos, arsenic, chromium, nickel, beryllium
• Air pollution
• Prior lung disease (IPF, COPD increase risk)

Clinical Presentation

• Local effects: cough, hemoptysis, dyspnea, post-obstructive pneumonia
• Regional spread: pleural effusion, hoarseness (recurrent laryngeal nerve), dysphagia (esophageal compression), SVC syndrome (facial/neck swelling)
• Pancoast tumor (superior sulcus): shoulder pain, Horner syndrome (ptosis, miosis, anhidrosis)
• Paraneoplastic syndromes (more common in SCLC):
  • SIADH (hyponatremia)
  • Ectopic ACTH (Cushing syndrome)
  • Eaton-Lambert myasthenic syndrome
  • Hypercalcemia (PTHrP - squamous cell)
  • Digital clubbing, hypertrophic osteoarthropathy

Staging

• NSCLC: TNM staging (Stage I-IV); Stage I-IIIa potentially resectable
• SCLC: Limited stage (one hemithorax, treatable within single radiation field) vs. Extensive stage

Treatment

• NSCLC:
  • Resectable (Stage I-II): surgical resection ± adjuvant chemotherapy
  • Locally advanced (Stage III): chemoradiotherapy ± immunotherapy
  • Metastatic (Stage IV): tyrosine kinase inhibitors for driver mutations (erlotinib/osimertinib for EGFR, alectinib for ALK, crizotinib/lorlatinib for ROS1/MET); immunotherapy (pembrolizumab) for high PD-L1; platinum-based chemotherapy
• SCLC:
  • Limited stage: cisplatin + etoposide + concurrent radiotherapy
  • Extensive stage: cisplatin/carboplatin + etoposide + atezolizumab (immunotherapy); prophylactic cranial irradiation

---

11. PLEURAL DISEASES

Pleural Effusion

• Heart failure, liver cirrhosis, nephrotic syndrome, hypothyroidism

• Pneumonia (parapneumonic/empyema), malignancy, TB, PE, collagen vascular disease

Pneumothorax

---

Key Spirometry Patterns Summary

• In COPD: TLC ↑ (hyperinflation), RV ↑, DLCO ↓ (emphysema)
• In restrictive disease: TLC ↓, RV ↓, DLCO ↓ (alveolar loss)

---

Sources

• Goldman-Cecil Medicine International Edition (2-Volume Set) - Chapters 76 (COPD), 77 (Cystic Fibrosis)
• Robbins & Kumar Basic Pathology - Chapter 11 (IPF/Lung Pathology)
• Murray & Nadel's Textbook of Respiratory Medicine (2-Volume) - Interstitial/Diffuse Lung Disease
• Fishman's Pulmonary Diseases and Disorders (2-Volume Set) - Pulmonary sections

---